A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 30 in the journal, Vaccine, published by Elsevier, http://www.sciencedirect.com/
Effective vaccines depend upon the human immune system recognizing a biological structure that is similar to that of a disease-causing organism. A manganese-peptide antioxidant complex of Deinococcus, developed by Uniformed Services University of the Health Sciences (USU) pathology professor Dr. Michael J. Daly and his team, has the remarkable property of protecting proteins from ionizing radiation damage but not protecting the genetic material (DNA or RNA) in viruses and bacteria. Using D. radiodurans, listed in the Guinness Book of World Records as “the world’s toughest bacterium” and which can withstand 3,000 times the levels of gamma radiation that human cells can, Daly found that a disease-causing organism (pathogen) can be exposed to gamma radiation in the presence of a Deinococcus Mn complex, and rendered non-replicative (killed) by overwhelming genetic damage, but still maintain the shape of key surface proteins needed to mount a highly protective immune response. This approach was successfully implemented on viruses for the first time by scientists in the USU lab of the late Dr. Radha K. Maheshwari to produce vaccines against VEEV and Chikungunya virus.
This approach offers a simple, rapid, cost effective and potentially universal inactivation strategy that can be applied to any pathogen requiring immediate attention, for example, Ebola and Zika viruses.
“Application of this methodology has the potential to revolutionize all future vaccine development” says Dr. Paridhi Gupta, a scientist in the Maheshwari laboratory, and the study’s co-lead author.
The Latest on: Vaccine development
Conjugate Vaccine Market Comprehensive Analysis and Future Estimations 2023 with Trends and Future Prospects Details for Business Development
on July 16, 2018 at 7:58 am
Conjugate Vaccines are formed by covalently bonding a weak antigen to the strong antigen. This is done to boost the hosts’ immunological response. The poor antigen is a polysaccharide that is attached ... […]
Polio (Poliomyelitis) Vaccines Market Development and Key Manufacturers: Sanofi, GSK, Bibcol, Serum Institute, Tiantan Biological
on July 13, 2018 at 10:49 am
The report on “Global Polio (Poliomyelitis) Vaccines Market” is a professional report which provides thorough knowledge along with complete information pertaining to the Polio (Poliomyelitis) Vaccines ... […]
3-D structure of 1918 influenza virus-like particles created
on July 11, 2018 at 12:28 pm
NIH/National Institute of Allergy and Infectious Diseases. (2018, July 11). 3-D structure of 1918 influenza virus-like particles created: Details could advance vaccine development for several human di... […]
Advances In Seasonal Influenza Vaccine Development
on July 9, 2018 at 7:03 am
Vaccine development is a long process that can take 10 or more years and involves public and private funding. Vaccines revenues are estimated to grow to 5.7 billion USD by 2019 from 3.3 billion USD in ... […]
Journal Highlight: The expanding role of mass spectrometry in the field of vaccine development
on July 9, 2018 at 1:34 am
Abstract: Biological mass spectrometry has evolved as a core analytical technology in the last decade mainly because of its unparalleled ability to perform qualitative as well as quantitative profilin... […]
via Google News and Bing News